Covid new strain: How India is preparing to tackle UK & variants of virus
COVID-19 vaccines will work against new variants of the virus and there is no evidence that current vaccines will fail to protect against the SARS-CoV-2 mutants reported from the UK or South Africa, the government said on Tuesday.
NITI Aayog member (health) Dr V K Paul said there has been a consistent decline in the number of new COVID-19 cases and deaths which is reassuring given the current scenario across the world.
The government briefed on how it plans to deal with the new variants of the virus.
People who have had major sinus surgery should consult their ENT doctor before undergoing the COVID-19 swab testing, a new research suggested. The findings of the study were published in the journal 'JAMA Otolaryngology - Head and Neck Surgery'. Issues include incorrect angling of the swab and inappropriate depth of insertion. If the swab angle is too high, a puncture may occur. The sinuses can protect the skull base to a degree, said Dr Chen. Injury from incorrect nasopharyngeal swab technique, while rare, may include cerebrospinal fluid leakage or severe bleeding. Polymerase chain reaction via nasopharyngeal swabs is a test frequently used to detect SARS-CoV-2 infection.
Member of NITI Aayog, Dr. VK Paul on April 19 said that the production of Remdesivir would be aimed at scaling up to 76 lakh vials per month. Dr. VK Paul said, "Air-borne transmission is more prevalent than surface transmission. As for Remdesivir production, it had gone down but now from 27 lakh vials/month, it has been scaled up to 40 lakh vials/month while aiming for 76 lakh vials/month."
Member of NITI Aayog, Dr. VK Paul on April 19 said that this year there is 32% positivity among people less than 30 years of age, it was 31% last year. Dr. VK Paul said, "In last pandemic wave, people under 30 yrs of age constituted 31% positive cases. It's 32% this year. People, between 30-45 years of age, testing positive remain same at 21% as was last year. There's no excess rate of young people testing positive."
During press conference held in Delhi, Niti Aayog's Dr VK Paul spoke on Remdesivir, which is an anti-viral drug for COVID-19. "There is no question of use of Remdesivir in home setting. This is required for those individuals who require hospitalisation and are on oxygen. It should only be use in hospital and not to be procured from chemist shops. We appeal that there should be rational use of Remdesivir. The drug is available in sufficient numbers. We appeal to the physicians' community for rational, judicious, and correct use of the drug," said Dr VK Paul.
In some cases, immune cells in the lungs can contribute to worsening a virus attack. In a new study, researchers at Karolinska Institutet in Sweden describe how different kinds of immune cells, called..